Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Joe Copia who wrote (75242)	12/22/2000 9:17:09 AM
From: Joe Copia	Read Replies (2) \| Respond to of 150070

A potential rise? (pun intended) Friday December 22, 4:22 am Eastern Time Vivus erectile dysfunction band wins OTC approval MOUNTAIN VIEW, Calif., Dec 22 (Reuters) -Pharmaceutical company Vivus Inc. (NasdaqNM:VVUS -news) on Friday said its prescription erectile dysfunction treatment, Actis, has been cleared by regulators to sell over the counter. Vivus, which in October withdrew its new drug application for erectile dysfunction treatment Alibra, said it has been selling Actis since 1997. Actis is a penile band that provides temporary relief from venous leak, which causes erectile dysfunction. ``Our ACTIS OTC marketing efforts have already begun,'' said Terry Nida, the company's vice president of marketing. ``Our plan calls for selling ACTIS through major pharmacy channels and through e-commerce efforts. Given its safety record, we expect that the product will be well received by consumers.'' Actis will be sold internationally by Abbott Laboratories Inc. (NYSE:ABT - news), Vivus said. Shares of Vivus, which specializes in sexual dysfunction treatments, closed up 1/16 at $1-15/16 in trading on the Nasdaq, well below their 52-week high of $11-1/4 and above a yearly low of $1-9/16.